Fenofibrate is a safe and inexpensive orally administered fibric acid derivative conventionally used to treat dyslipidemia. Two large randomized clinical trials, the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) studies, demonstrated the benefit of oral fenofibrate in the treatment of patients with type 2 diabetes and diabetic retinopathy (DR), including reduced disease progression and need for laser treatment for diabetic macular edema and proliferative diabetic retinopathy. These findings are supported by results of experimental studies, which have demonstrated beneficial effects of fenofibrate ameliorating retinal vascular leakage and leukostasis, downregulating vascular endothelial growth factor, and reducing endothelial cell and pericyte loss, among others; all of these are characteristic features of DR. In spite of this evidence, fenofibrate is not prescribed routinely for treating patients with diabetes and DR. In FIELD and ACCORD studies, retinopathy was not the primary outcome and this may explain, at least partly, its lack of use for this indication. New trials are now underway to specifically address the effects of fenofibrate in DR; these trials will provide additional and robust data that may support current evidence favoring the use of fenofibrate in this common microvascular complication of diabetes.
injections of steroids. 3, 4 For patients with PDR, laser panretinal photocoagulation (PRP) remains the treatment of choice. Results of 2 recently published randomized clinical trials (RCTs) suggest that anti-VEGFs could also be used to treat PDR with less than high-risk characteristics, which comprised the great majority of patients recruited in these trials. 5, 6 Anti-VEGFs may be costeffective to treat people with concomitant DME and PDR. 7 Evidence suggests that macular laser photocoagulation (focal or grid) is clinically effective and cost-effective only in patients with mild DME (less than 400 μm in central retinal thickness as determined by spectral-domain optical coherence tomography) 3, 4 and seems to be clinically effective also for those with localized forms of DME. Panretinal photocoaculation, though very effective in treating PDR, may affect the peripheral vision and, therefore, a patient's ability to drive. Intravitreal anti-VEGF injections are costly and invasive. They have potential risks including increased intraocular pressure, cataract, retinal detachment, and infection (endophthalmitis), with the latter having potentially very severe consequences (total sight loss). Such injections also require very regular retreatments and follow-up. Not all patients with DME or PDR respond to current therapies. Thus, there is a clear need to develop improved treatment strategies.
Very large RCTs have shown that an orally administered safe and inexpensive drug, fenofibrate, can reduce the progression of DR and the need for treatment of DME and PDR in patients with type 2 diabetes. Fenofibrate, however, is not routinely prescribed for patients with diabetes.
Herein, we provide a summary of the effects of fenofibrate on the retina and the evidence that supports its use in patients with diabetes.
PHARMACOLOGY AND POTENTIAL MECHANISMS OF ACTION OF FENOFIBRATE
Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. Fenofibrate is metabolized to fenofibric acid, which then binds to the nuclear hormone receptor PPARα. The bound PPARα receptor then forms a heterodimer with the retinoid X receptor, before this heterodimer binds to specific peroxisome proliferator response elements to activate target gene transcription. 8 Fibrates act by primarily reducing circulating levels of triglycerides and low-density lipoprotein (LDL) cholesterol. 9 This seems to be achieved through PPAR-mediated upregulation of lipoprotein lipase and inhibition of apolipoprotein C-III, with the combined effect of increasing the catabolism of triglyceride-rich particles and very LDL. 10, 11 High-density lipoprotein (HDL) cholesterol levels tend to increase when baseline plasma levels are low, through the PPAR-dependent induction of hepatic apoA-II synthesis.
By reducing lipids in blood, fenofibrate could confer a benefit for the treatment of patients with DR by reducing hard exudation in the retina (see sections below). In addition, fenofibrate may have added benefit by reducing levels of modified LDL within the retina. 13 It has been shown that intraretinal extravasated modified LDL increases with increasing severity of DR and is toxic to retinal capillary endothelial cells and pericytes. 14, 15 The beneficial effects of fenofibrate observed in the retina in patients with diabetes, however, seem to be independent and additional to its lipid-lowering effects.
In experimental models of type 1 and type 2 diabetes, expression of PPARα was found to be downregulated in the retina. 16 Furthermore, downregulation of PPARα occurred in cultured retinal cells [retinal pigment epithelial cells, Müller cells, and pericytes] exposed to high glucose concentrations. 16 Moreover, PPARα knockout diabetic mice developed more severe DR changes. 16 Increased blood vessel permeability and retinal vascular leakage were ameliorated by PPARα overexpression 16 and specifically by administration of oral fenofibrate. 17 Fenofibric acid has also been shown to reduce the increased in vitro retinal endothelial cell permeability which is induced by high glucose level. 18 Early changes in DR are characterized histologically by pericyte and endothelial cell loss. 2 It has been shown that fenofibrate protects both retinal endothelial cells and pericytes from undergoing apoptosis. 19 This antiapoptotic effect was replicated in human glomerular endothelial cells. 20 Breakdown of the inner and outer blood retinal barriers with subsequent vascular leakage and the development of neovascularization are characteristic features of DR and, specifically, of DME and PDR, respectively; increased VEGF seems to play a major role on their occurrence. Under hypoxic conditions, like those existing in the diabetic retina, hypoxia-inducible factor 1α (HIF-1α) induces upregulation of VEGF. It has been shown that fenofibrate is able to block the activation of HIF-1α and reduce VEGF expression. 17, 21 Retinal pigment epithelial cells are responsible for the maintenance of the outer blood retinal barrier; fenofibric acid has been shown to have a protective effect in the retinal pigment epithelium, preventing disruption of the outer blood retinal barrier. [22] [23] [24] There is some evidence that fenofibrate can have neuroprotective effects. Fenofibrate ameliorated retinal nerve fiber layer loss occurring in patients with type 2 diabetes mellitus. 25 This neuroprotective effect has also been demonstrated in a diabetic mouse model, with mice fed oral fenofibric acid showing a reduction in ganglion cell layer apoptosis and improvement in function on electroretinography testing. 26 
DOSE
Fenofibrate has been used at different doses, ranging from 135 mg to 200 mg per day. [27] [28] [29] [30] The manufacturer advises a maximum dose of 200 mg daily if the patient is also taking a statin. 31 The dose should be reduced to 67 mg daily if there is mild-to-moderate renal impairment and is contraindicated if there is severe renal impairment.
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CLINICAL EVIDENCE SUPPORTING THE USE OF FENOFIBRATE FOR DR
Clofibrate was the first lipid-lowering agent that was noted to have an impact on the clinical course of DR. Several trials conducted in the United Kingdom found that long-term use of clofibrate reduced the severity of hard exudates in DR. [32] [33] [34] Two of these studies found that patients treated with clofibrate had a reduction in the area of retina involved by hard exudates, but this reduction was not associated with an improvement in visual acuity. 32, 34 This effect on hard exudation seemed to be independent of the effect of clofibrate on serum lipid concentrations. 32 Clofibrate, however, had an unacceptable side-effect profile and was never widely used. 35 Two large RCTs, the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, have shown clear benefits of fenofibrate in patients with DR. 28, 36 The FIELD study was a multicenter RCT aiming at determining the effect of fenofibrate on microvascular and macrovascular complications in 9757 patients with type 2 diabetes mellitus. 37 Patients were assigned 1:1 to receive fenofibrate 200 mg/day or placebo. A substudy of 1012 eligible patients examined the effect of fenofibrate on the progression of DR. 28 The primary endpoint was defined as a 2-step increase in the Early Treatment Diabetic Retinopathy Study (ETDRS) grade after 2 years or more of follow-up, based on color fundus photographs of the macula. Secondary endpoints included the need for laser treatment for the complications of DR (DME and PDR) and the de novo development of DME. In patients with preexisting retinopathy, fenofibrate reduced DR progression (3.1% and 14.6% for fenofibrate and placebo, respectively, P = 0.004). Furthermore, the use of macular laser to treat DME or PRP to treat PDR was also reduced, with a requirement for first laser treatment during the 5-year follow-up period being significantly lower in the fenofibrate group when compared with placebo [3.4% and 4.9% for fenofibrate and placebo, respectively; hazard ratio (HR), 0.69; P = 0.0002]. A protective effect was observed within 8 months of treatment allocation. In this study, fenofibrate did not reduce the occurrence of new retinopathy in those with no overt retinopathy at baseline, or the occurrence or progression of hard exudation (accumulation of lipid) in the retina.
The beneficial effects of fenofibrate in the FIELD study did not seem to be related to its effects on circulating lipid concentrations. Fenofibrate produced an initial reduction in plasma concentrations of total cholesterol, LDL cholesterol and triglycerides, with a small increase in HDL cholesterol concentration, compared with the placebo group. However, these differences decreased over the course of the study. 37 Lipid concentrations at baseline did not seem to affect the likelihood of developing retinopathy requiring laser treatment during the follow-up.
The ACCORD study was a randomized clinical trial of 10,251 individuals with type 2 diabetes mellitus to evaluate the effect of intensive medical treatment of hyperglycemia, hypertension, and dyslipidemia on cardiovascular outcomes. 38 The ACCORD Eye study specifically examined the effect of these interventions on the progression of DR in 2856 subjects. 36 The primary outcome measure was the composite endpoint of either a 3-step progression (ETDRS person scale) of DR or the development of PDR requiring laser therapy or vitrectomy over a 4-year follow-up period. A total of 1093 patients in the ACCORD Eye study were also enrolled in the ACCORD Lipid study. Patients were randomized to receive either 160 mg of fenofibrate plus simvastatin daily or placebo plus simvastatin. There was a reduction in triglyceride levels in the group treated with fenofibrate. The fenofibrate-treated group also demonstrated a significant decrease in the rate of progression of DR at 4 years (6.1% and 9.8% in fenofibrate + simvastatin and placebo + simvastatin, respectively, P = 0.0049).
As in the FIELD study, in the ACCORD Eye study there was no evidence of a beneficial effect of fenofibrate in patients with no retinopathy at baseline but a large benefit was observed for those with DR.
A follow-on study of the ACCORD cohort found that the protective effect of fenofibrate did not persist after the cessation of fenofibrate, unlike the metabolic memory effect observed with prior intensive glycemic control. 39 
EFFECTS OF FENOFIBRATE ON DME
In the FIELD study, stereoscopic color fundus photographs of the macula were used to identify DME. 28 Fenofibrate reduced the proportion of patients developing de novo DME during the study period, but differences between fenofibrate and placebo groups did not reach statistical significance (0.8% and 2.2% for fenofibrate and placebo, respectively, P = 0.09). Macular edema was also assessed using stereoscopic fundus photographs in the ACCORD study which revealed that only 10% of patients were noted to have DME at baseline and edema was noted to be mild or very mild. 30 In this study, fenofibrate did not seem to be protective against the development of DME compared with placebo.
A masked, randomized, placebo-controlled RCT evaluated the effect of oral fenofibrate at a dose of 135 mg/day in 110 subjects with DME not requiring immediate focal macular laser or intravitreal anti-VEGF. 30 In this RCT, fenofibrate was found to reduce total macular volume, measured using timedomain optical coherence tomography (TD-OCT), after 1 year of treatment. This effect, however, did not reach statistical significance [−0.25 mm between-group comparison for the fenofibric acid group versus placebo group; 95% confidence interval (CI), −0.645-0.155; P = 0.227]. 30 A smaller study by Srinivasan et al 27 examined the impact of oral fenofibrate at a dose of 160 mg/day for 6 months on central macular thickness (CMT) in 50 patients with DME who were also receiving intravitreal anti-VEGF injections. As measured on TD-OCT, CMT decreased more in the fenofibrate group than in the control group (mean reduction of 136 μm for fenofibrate versus 83 μm for control, P = 0.004). This effect was independent of the reduction in triglyceride levels.
EFFECTS OF FENOFIBRATE ON VISUAL ACUITY
Similar numbers of patients in fenofibrate and placebo groups in the FIELD study experienced the loss of 2 Snellen lines (30.7% in the fenofibrate group versus 29.1% in the placebo group). 28 Similarly, in the ACCORD Eye study a 3-line worsening of vision (ETDRS letter score) occurred at a similar rate in patients in the fenofibrate and placebo groups (3.3% of patients/ year in the fenofibrate group versus 3.5% of patients/year in the placebo group, P = 0.48).
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In the smaller study of patients with DME by Srinivasan et al, 27 a higher number of participants in the fenofibrate group achieved a 2-line (logarithm of the minimum angle of resolution) improvement in visual acuity when compared with those in the placebo group, but with differences not statistically significant (7 patients in the fenofibrate group versus 3 patients in the control group, P = 0.186).
ADDITIONAL BENEFITS OF FENOFIBRATE ON THE RETINA
Elevated total serum cholesterol and/or LDL levels have been shown in studies, including the ETDRS, to be associated with the presence and amount of hard exudation in the retina and independently associated with an increased risk of visual imparment. 40 ,41 Furthermore, a raised triglyceride level is a risk factor for the development of high-risk PDR. 42 The severity of retinopathy in people with type 1 diabetes was positively associated with triglyceride levels and negatively associated with HDL levels. 43 High serum lipid levels were associated with the presence of macular exudates and macular edema in patients with type 1 and type 2 diabetes in a post-hoc analysis of serum lipid levels of patients in the Diabetes Control and Complications Trial and a small case-control study (n = 54), respectively. [44] [45] [46] By reducing cholesterol and LDL, and increasing HDL, fenofibrate should provide additional long-term benefits to the retina.
In a case-control study including 89 patients with type 2 diabetes and no overt retinopathy or nonproliferative DR, it was observed that nerve fiber layer thickness was reduced in the group of patients not receiving fenofibrate when compared with fenofibrate users. 25 
ADDITIONAL BENEFITS OF FENOFIBRATE IN OTHER COMORBIDITIES IN PATIENTS WITH DIABETES
Results from the FIELD study demonstrated a reduction in the rate of nonfatal myocardial infarction in the fenofibrate group versus placebo (HR, 0.76; 95% CI, 0.62-0.94; P = 0.010), along with a reduction in minor amputations (18 events in the fenofibrate group versus 34 in the placebo group; HR, 0.53; 95% CI, 0.30-0.94; P = 0.027). 47 Fenofibrate may cause a reversible increase in plasma creatinine, but there is evidence that it can delay albuminuria and glomerular filtration rate loss over 5 years. 48 There is experimental evidence to suggest that fenofibrate may have an important role in diabetic peripheral neuropathy. 49 
SAFETY OF FENOFIBRATE
Fenofibrate has a very favorable safety profile. [50] [51] [52] It is as well-tolerated as statin monotherapy and combining fenofibrate with statin therapy does not seem to increase the rate of adverse effects. 53, 54 The most common adverse effect of fenofibrate is an elevation of the hepatic enzyme aminotransferase. 53 Patients taking fenofibrate should have monitoring of aminotransferase levels and discontinuation should be considered if the levels persist above 3 times the upper limit of normal. 55 It is also recommended that serum creatinine levels are monitored during the first 3 months of treatment and periodically thereafter. 31 In the FIELD study, fenofibrate had a similar safety profile to placebo, although there were small increases in the rare events of pancreatitis and pulmonary embolism in the fenofibrate group. 37 In the ACCORD trial, serum creatinine levels increased in both the fenofibrate and placebo groups (mean increase from 82 to 97 μmol/L in the fenofibrate group versus 82 to 92 μmol/L in the placebo group). 56 However, there was a lower incidence of both microalbuminuria and macroalbuminuria in the fenofibrate group than in the placebo group. 56 It is important to consider a patient's comorbidities when prescribing fenofibrate. Patients with chronic renal failure who are prescribed fenofibrate along with a statin may be at increased risk of rhabdomyolysis. 57 Although this is a severe adverse effect, recovery is typical after discontinuation of the fibrate and appropriate hydration. Fenofibrate is thought to possibly potentiate the anticoagulant effect of warfarin and thus close monitoring of a patient's international normalized ratio is recommended after initiating treatment with fenofibrate. 58 
CONCLUSIONS
There is evidence supporting the beneficial effect of fenofibrate in DR. Fenofibrate, however, is scarcely prescribed for patients with diabetes. This may be because the FIELD and AC-CORD studies, although both of them are very large RCTs, did not have the effect of fenofibrate on DR as the primary outcome. It may also relate to the fact that fenofibrate is generic and there is no commercial push for its use. Fenofibrate has been licensed in Australia and Singapore for the treatment of DR. Trials are now ongoing to further determine the beneficial effects of fenofibrate, specifically in reducing macular thickness and volume in patients with type 1 diabetes and reducing the rate of progression of nonproliferative DR. 59, 60 Given the current existing evidence and safety profile of fenofibrate, adding this drug to current treatment strategies for patients with diabetes should be seriously considered, especially for those with type 2 diabetes to which most of the current available evidence applies.
